Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

Basel, Switzerland – 25 February 2020

  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
  • Leishmaniasis, which is transmitted by the sandfly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year

Novartis and DNDi have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.